Long-awaited results proving two classes of cardiovascular disease drugs can reduce the risk of heart attack and stroke in 2018 could cause sales to soar for Amgen (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), and Amarin Corp (NASDAQ: AMRN).
In this clip from The Motley Fool’s Industry Focus: Healthcare, analyst Shannon Jones is joined by Todd Campbell to discuss how investors were rewarded in 2018.
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: